Journals / Journal of Biotechnology and Strategic Health Research / 2017 / Mikrobiyota

Cardiovasculer Diseases and Microbiota

Kardiyovasküler Hastalıklar ve Mikrobiyota

Pages
141–147
Publication Date
2017-11-15
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The modification of the intestinal microbiota with products like probiotic, prebiotic and symbiotic becomes increasingly important treatment method.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Cardiovascular Diseases (CVD) are the most common cause of death in worldwide It accounts for 31% of all deaths in the world.
📊
Key Findings & Data:The genome of microorganisms is called “ microbiome “ The human body is composed of 10% of its own cells and 90% of the existing microbial cells.Intestinal microbiota; carries out very important tasks on the physiological, metabolic and immunological systems in our body.Intestinal bacteria that control the necessary metabolic processes by assuming the role of energy carrier or releasing immunomodulating substances because of this it is now defi ned as a new “metabolic organ”.
💡
Conclusion & Impact:The modification of the intestinal microbiota with products like probiotic, prebiotic and symbiotic becomes increasingly important treatment method.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:İntestinal mikrobiyota · kardiyovasküler hastalıklar · Mikrobiyota düzenlenmesi

Abstract

Cardiovascular Diseases (CVD) are the most common cause of death in worldwide It accounts for 31% of all deaths in the world. Risk factors for CVD are smoking, unhealthy diet, obesity, physical inactivity, high blood pressure (hypertension), high blood fat and diabetes Bacteria that have been settled in various parts of the body such as skin, mouth, vagina, intestines are called “floras”, new name is called “microbiota”. The genome of microorganisms is called “ microbiome “ The human body is composed of 10% of its own cells and 90% of the existing microbial cells.Intestinal microbiota; carries out very important tasks on the physiological, metabolic and immunological systems in our body.Intestinal bacteria that control the necessary metabolic processes by assuming the role of energy carrier or releasing immunomodulating substances because of this it is now defi ned as a new “metabolic organ”. Recent studies with intestinal microbiology have shown that microbiota is associated with both metabolic and cardiovascular diseases. Intestinal microbiota associated with many diseases has made it possible to use microbiota modification in therapy. The modification of the intestinal microbiota with products like probiotic, prebiotic and symbiotic becomes increasingly important treatment method.

Özet

Kardiyovasküler Hastalıklar (KVH) dünya genelinde ölümlerin en sık nedenidir. Dünyadaki tüm ölümlerin %31’ini oluşturmaktadır. KVH için sigara kullanımı, sağlıksız beslenme, obezite, fi ziksel inaktivite, yüksek kan basıncı (hipertansiyon), yüksek kan yağları ve diyabet gibi risk faktörleri mevcuttur Vücudun deri, ağız, vajina, bağırsaklar gibi çeşitli bölgelerinde yerleşmiş bakterilere o bölgenin “florası”, yeni adıyla “mikrobiyota”sı denmektedir. Mikroorganizmaların genomuna ise “mikrobiyom” adı verilmektedir. İnsan vücudu %10 kendi hücresi ve % 90’ı mevcut konağa yerleşmiş mikrobiya hücrelerden oluşmaktadır. İntestinal mikrobiyota; vücudumuzda fi zyolojik, metabolik ve immun sistem üzerinde oldukça önemli görevler üstlenmektedir. Enerji taşıyıcı rolü üstlenerek veya immun modüle edici maddeleri serbest bırakarak gerekli metabolik süreçleri kontrol eden bağırsak bakterileri bu nedenle günümüzde yeni bir “metabolik organ” olarak tanımlanmaktadır. Bağırsak Mikrobiyotası ile son dönemde yapılan çalışmalarda Mikrobiyota ile hem metabolik hem de kardiyovasküler hastalıklar arasında ilişki olduğu gösterilmiştir İntestinal mikrobiyotanın birçok hastalıkla ilişkili bulunması mikrobiyota modifi kasyonunun tedavide kullanılabilirliğini gündeme getirmiştir.İntestinal mikrobiyotanın probiyotik, prebiyotik ve simbiyotik gibi ürünlerle modifi ye edilmesi giderek önem kazanan tedavi yöntemi olmaktadır.

🔖

Cite This Article

VARIM, P., VATAN, M. B., VARIM, C. (2017). Cardiovasculer Diseases and Microbiota. Journal of Biotechnology and Strategic Health Research, Mikrobiyota, 141–147. https://ajindex.com/articles/774625

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (2)

  1. Global status report on noncommunicable diseases 2010.
  2. Geneva, World Health Organization, 2011 2. Emoto T, Yamashita T, Sasaki N et al. Analysis of gut microbiota in coronary artery disease patients: a possible link between gut microbiota and coronary artery disease. J. Atheroscler. Thromb. 2016;23(8):908–921 3. Belkaid Y, Hand TW. Role of the microbiota in immunity and infl ammation. Cell 2014;157:121–41 4. Ley RE, Peterson DA, Gordon JI. Ecological and evolutionary forces shaping microbial diversity in the human intestine. Cell. 2006;124(4):837–848. 5. Bull M.J, Plummer N.T. Part 1: The Human Gut Microbiome in Health and Disease. In: Integrative Medicine: A Clinician’s Journal 2014;13(6):17-22. 6. Jandhyala SM, Talukdar R, Subramanyam C, Vuyyuru H, Sasikala M, Reddy DN. Role of the normal gut microbiota. World Journal of Gastroenterology: WJG. 2015;21(29):8787-8803. 7. Altuntaş Y, Batman A Mikrobiyota ve metabolik sendrom Turk Kardiyol Dern Ars 2017;45(3):286–296 8. NIH HMP Working Group, Peterson J, Garges S, Giovanni M, McInnes P, Wang L, Schloss JA, Bonazzi V, McEwen JE, Wetterstrand KA, Deal C, Baker CC, Di Francesco V, Howcroft TK, Karp RW, Lunsford RD, Wellington CR, Belachew T, Wright M, Giblin C, David H, Mills M, Salomon R, Mullins C, Akolkar B, Begg L, Davis C, Grandison L, Humble M, Khalsa J, Little AR, Peavy H, Pontzer C, Portnoy M, Sayre MH, Starke-Reed P, Zakhari S, Read J, Watson B, Guyer M. The NIH Human Microbiome Project. Genome Res. 2009 Dec;19(12):2317-23. 9. Kasai C, Sugimoto K, Moritani I, et al. Comparison of the gut microbiota composition between obese and non-obese individuals in a Japanese population, as analyzed by terminal restriction fragment length polymorphism and next-generation sequencing. BMC Gastroenterology. 2015;15:100. 10. Kallus SJ, Brandt LJ. The intestinal microbiota and obesity. J Clin Gastroenterol 2012;46:16-24. 11. Hooper LV, Wong MH, Thelin A, et al. Molecular analysis of commensal host-microbial relationships in the intestine. Science 2001;291:881-433. 12. Duncan SH, Lobley GE, Holtrop G, et al. Human colonic microbiota associated with diet, obesity and weight loss. Int J Obes 2008;32:1720-4. 13. Mackowiak PA. The normal microbial fl ora. N Engl J Med 1982;307:83–93. 14. Schwiertz A, Taras D, Schäfer K, Beijer S, Bos NA, Donus C, et al. Microbiota and SCFA in lean and overweight healthy subjects. Obesity (Silver Spring) 2010;18:190–5. 15. Nadal I, Santacruz A, Marcos A, Warnberg J, Garagorri JM,Moreno L